Medgadget highlighted a new treatment option that is in clinical trials for the treatment of coronary artery disease, an ultrasound system to stimulate blood vessel formation in ischemic areas of heart muscle.
Extracorporeal Shockwave Myocardial Revascularization (ESMR) is under development by Medispec, a Germantown, MD, company. The technology in its Cardiospec system uses Extracorporal Shockwaves coupled with R-wave ECG gating to stimulate angiogenesis in ischemic areas of myocardium. Like transmyocardial laser revascularization (loosely comparable), which stimulates the formation of new blood vessels in ischemic myocardium, the ESMR system employs single-pulse, high-pressure ultrasound waves that have been shown to increase blood vessel formation and result in increased myocardial perfusion.
Medgadget notes that ESMR is designed to "complement existing therapies for myocardial ischemia such as nitrates, CABG or angioplasty, and to provide an alternative treatment option for those patients who are candidates for more invasive procedures".
For the sake of keeping track of the seemingly ever-expanding range of therapeutic options for coronary artery disease, MedMarket Diligence has produced the following treatment map and now has added ESMR to the map:
In reality, there are numerous complementary treatments for CAD, such that the available methods to "map" the alternatives (we are using the open source application, FreeMind) have limited ability to accurately represent the options visually.
MedMarket Diligence published the Worldwide Drug-Eluting Stent Market report #C245.